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ABSTRACT
Nitric oxide (NO) has been shown to possess many Anti-inflammatory effects. Ascorbic
acid which is naturally present in human body is known to react with S-nitrosothiols
(RSNO) directly to reduce RSNO to NO and produce free thiol groups, if present in more
than millimolar concentration. Higher concentration of ascorbic acid is required because
the reduction of RSNO is not caused by ascorbate instead, but instead a decomposed
product of ascorbic acid. S-Nitroso-N-Acetylpenicillamine is used as an NO donor. An
HPLC method is used for determination of the degradation product of ascorbic acid and
simultaneously identifying the compound responsible for NO production from RSNO by
running the compound through Nitric Oxide Analyzer. Once the compound is identified it
has a potential medical use for NO production. For example, it could provide a means that
initiates RSNO decomposition in polymeric biomaterials. Thus, increasing the
functionality of the medical device coated with such materials and preventing thrombus
formation

viii

1. INTRODUCTION
With the increasing size of the population and the increasing multitude of illnesses
such as diabetic, cardiovascular and neurological disorders which cannot be mitigated
alone with medications, there is an increasing demand for implantable devices
[1]. Over the last 60 year’s implantable devices have undergone a significant
transformation becoming a valuable tool for monitoring and measuring physiological
conditions. Success of these devices has heavily relied on the development of electronic
technologies capable of interfacing with living tissues and organs at the micro and
nanoscale level [2]. With increased in vivo stability, miniaturization along with some other
parameters has led to the development of implantable electronic devices, such as sensors,
cardiac pacemakers, implantable cardioverter defibrillators, cochlear implant, and bone
stimulator, to name a few. These devices encompass a wide range of duration of intended
use, level of invasiveness and device complexity. For example, needle-type glucose
sensors are placed in subcutaneous tissue and intended to monitor glucose levels in
interstitial fluid that is related to blood glucose levels. Another example are prosthetic knee
implants which are intended to be imbedded in body within the patient and restore
physiological function of the knee joint for 10 years.
Halperin et al. report that over 25 million US citizens are reliant on implantable
medical devices for life-critical functions [3]. Despite of substantial innovations in the
fabrication and application of implantable biomedical systems since the first implantable
heart pacemaker of 1958, the modern implants patient is still faced with several challenges.
Long-term reliability of the device is extremely important considering the high cost and
time associated with surgical implantation along with patient recovery. The location of the
implant space is a chemically harsh environment, where the surface of the implant will be
continuously attacked by the highly conductive and corrosive physiological medium which
also carries a variety of biochemically reactive organic molecules and metabolically active
cells. The drive towards small, light, and flexible devices may affect the mechanical
robustness of implants. The ensuing in vivo degradation and loss of integrity may be
detrimental to the performance of the device, potentially leading to the device failure.
Studies to improve the quality and design of both intravascular and subcutaneous sensors
has been carried out since early1960s [4]. Only a handful of sensors have succeeded in the
in vivo environment, with most failures due to the unpredictable performance resulting
from the robust and dynamic biological response mounted by the body in response to the
foreign device within the physiological system.
Achieving biocompatibility is a complex matter due to the dynamic host response
to the synthetic and organic material used for device production. The host response must
be balanced with the intended life time of a device and what is required of the device for
appropriate functionality within the body. Focusing on the specific case of implanted
sensors, one of the solutions under investigation is using a biodegradable material for
fabrication of device which will allow controlled dissociation over time. Degradation
1

products will cause minimal toxic response and are removed from the implantation site by
normal metabolic activity [5].
One such example of biodegradable materials is using Magnesium based alloys. Stent
used in cardiovascular application can be made from magnesium alloy. It has many
advantages i.e. high biocompatibility (Mg is present in the body and will not be recognized
as foreign material) , Alloy’s element are dissolved in the human body (no toxic waste),
not visible be X-ray or CT scan (no artifacts) . However, they do have some limitations
like low corrosion resistant and suboptimal biocompatibility. Coating technology is one of
the leading approach used to overcome these problems. Coatings on Mg-based stents can
vary from metal and inorganic coatings to biodegradable coatings. Among these,
biodegradable polymer coatings with drug-eluting features might be a better choice
because of their advanced biocompatibility and capability to reduce late restenosis
compared with other coatings. Developing implantable electronic device with
biodegradable, non-toxic electronic materials on a such a small scale is difficult. A
combination of robust and reliable electronics with a bio resorbable polymer platform
offers both the flexibility of the device and sufficient bulk degradation that the immune
response to the remaining material is minimal. For the technology to be clinically implanted
certain challenges such as controlling degradation kinetics and biocompatibility of the
device should be addressed. A review of the major issues that are involved in biological
response to implanted devices follows, beginning with the risk of infection associated with
implanted devices, the tissue response toward implanted devices, and coagulation inspired
by implanted devices. By examining these separate processes, potential solutions to
overcoming the host response to implanted devices can be developed.

1.1. IMPLANT ASSOCIATED INFECTIONS
Implantable devices have undergone a significant development due to the advancement
in packaging designed to protect the indwelling device from hash physiological
environment. Nonetheless, the risk of infections resulting from bacteria adhering to the
implant is significant in terms of both morbidity and mortality of the patient and high costs
associated with treating these device-associated infections. The highly invasive nature of
the surgical procedure along with the health condition and inadequate immune response
from the patient contribute to the causes of implant associated infection. Depending upon
the severity of the infection treatment may involve localized antibiotic therapy to complete
removal of infected implant. The incidence of infections associated with cardiac pacemaker
implant ranges from 1%–19%, with 7%– 8% attributed to contamination during laboratory
handling or the event of implantation [7]. Typically, the pre- and post-operative pathways
are the most common pathways of biomaterial associated infection. If a patient is suffering
from diabetic disease or using anti-inflammatory medication like corticosteroids and other
immunosuppressive drugs may slow down surgical site healing and patient recovery,
making the host more susceptible to developing an infection [8]. In addition, pathogens,
2

can originate elsewhere in the body and spreading to the implant site via blood, this route
of infection is particularly important for devices that are in contact with the blood.
The physiochemical properties of the implanted surface render them susceptible for
colonization by bacteria. The non-living nature of the implant surface means that it does
not respond to the presence of bacteria nor does it produce chemical signals to notify the
surrounding tissues of the imminent danger. Certain combination of surface properties can
be employed to mitigate the host response to a certain level, but these modifications are
helpless against bacterial cells that manage to adhere to implant surfaces. Furthermore,
bacterial cells that adhere to implant surfaces release a significant amount of extracellular
matrix to form a biofilm around the implant. In this biofilm state, they are protected from
the host response and are not susceptible to systemic antibiotics. Hence, there has been
more emphasis on developing surfaces capable of both preventing the bacterial adhesion
and replication, and eliminating attached bacteria by releasing antibacterial drugs. The drug
eluting property can be imparted onto the implanted module via encapsulation or surface
modification. In addition to traditional antibiotics, a range of alternative antimicrobial
agents have been considered, including silver ions, nitric oxide, bioactive antibodies, and
other bactericidal compounds [9,10].

1.2. HOST RESPONSE TO FOREIGN MATERIALS
INFLAMMATION
Inflammation and Coagulation are two major factors that significantly impact the
function of the implanted device. When the properties of the surface materials are not
properly matched with the characteristics of the surrounding tissues and cells the longterm
utilization of the material may not be successful [11]. Surfaces of the implants may be
contaminated by bacteria or bacterial cells which induces an inflammatory response. The
physical presence of the implant, e.g., pressure it exudes onto the surrounding tissues and
organs, can also trigger inflammatory mechanisms where affected cells release a host of
chemical signalling molecules. Surgical intervention for introducing the implant triggers a
pro-inflammatory response which delays the tissue healing. After the implant is exposed
to chemically harsh environment, to the implant may begin to degrade as a result of this
cell-mediated inflammatory response. Furthermore, the loosening of the implant has been
linked to the increased incidence of inflammations, complications, and less successful
functional performance of the implant.
Device implantation and associated tissue injury triggers a cascade of inflammatory
and wound healing responses. The inflammatory response is comprised of two stages: acute
and chronic phases. The initial acute phase lasts from hours to days. The acute phase is
mostly responsible for cleaning the wounded site and provisional matrix formation. Vessels
dilate and excess blood flows into the injury site. Numerous blood and tissue proteins such
as cytokines and growth factors are released, and leukocytes adhere to the endothelium of
the blood vessels and infiltrate the injury site.
3

Monocytes are then called into the site and these differentiate into macrophages [12].
Persistent inflammatory stimuli without resolution, such as the continual presence of the
biomaterial/medical device, lead to chronic inflammation. Chronic inflammation is
histologically less uniform when compared to acute inflammation, and the wound healing
response is generally dependent on the size and/or degree of injury. This phase is generally
characterized by the presence of monocytes, macrophages, and lymphocytes, as well as the
proliferation of blood vessels and connective tissue to restructure the affected area. The
formation of blood vessels is essential to wound healing, supplying necessary nutrients.
Eventually, the granulation tissue is replaced by an extracellular matrix (ECM). The ECM
acts not only as a physical scaffold but also as a crucial modulator of the biological
processes, including differentiation, development regeneration, repair, as well tumor
progression [13]. The end stage of the foreign body response involves walling off the
implant by a vascular and collagenous fibrous capsule that is typically 50–200 µm in
thickness. This fibrous wall confines the implant and consequently prevents it from
interacting with the surrounding tissue.

4

Figure 1.1 Sequence of events involved in the foreign body response to an
implantable device.
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1.2.1 COAGULATION RESPONSE TO FOREIGN
MATERIALS
Intravascular implants offer more advantage for patience care and improving the
life style of the individual. However, they do face some major issues like size limitations
and biocompatibility. Sensors not only have to be smaller in size but also must function
fully in the presence of blood and the coagulation cascade.
Implantable devices as they come in contact with the blood, this will activate the
coagulation cascade [14]. The end result of this response is a device coated with the
provisional matrix that is a blood clot which contains metabolically active cells. This
encapsulation can deeply affect the functionality of the sensor and resulting embolism risks
for the patient of the blood clot breaks apart and travels to other locations within the
vasculature [15].
Most common example of implant being encapsulated with calcium deposits are
heart valves. Calcific deposits are seen on the heart valves within 3 years of
postimplantation. It occurs due to chemical interaction within the aldehyde groups
phospholipids and circulating calcium ions, immunological response. Calcification often
starts at the commissure and the basal area of the cusp. Calcification can lead to stenosis
due to cusp stiffening and regurgitation or incompetence, due to associated cusp tears.
Occasionally, calcific deposits on the surface of the cusps may embolize to distant sites.
The blood coagulation cascade is can be initiated by either the intrinsic pathway or
the extrinsic pathway. Details of the intrinsic cascade are shown in Figure 1 Briefly,
Initially, proteins adsorb on the surface of the sensor immediately upon implantation. The
composition of the blood bound proteins varies and change over the course. Composition
of proteins adsorbed on to the surface depends on the Vroman effect and the nature of the
implant (i.e. type of surface, curves, smooth etc.). Next platelet bound to these surface
proteins via expression of adhesion receptors (e.g. glycoprotein IIb/IIIa which binds to the
plasma ligand fibrinogen), contractile protein within the platelets tighten and the platelet
flattens to form “false-legs” or pseudopodia [16]. This enables them to cover more surface,
at the same time contraction causes degranulation of platelets. Degranulation releases a
number of chemicals including ADP and thromboxane A2. These chemicals are potent
platelet activators, thus attracting nearby platelets to the surface increasing the platelet
adhesion and aggregation. In the end, the implant surface will be coated with stabilized
activated platelet that binds with factor V to activate local thrombin. Thrombin once
formed interacts with fibrinogen to form a mesh of fibrin around the implant. Fibrin
interacts with platelets to Breaking of the thrombi and freely entering the circulating blood
causes poses a serious threat. Only presence of a monolayer of thrombus will not affect the
sensor or make it less responsive to the analyte.
However, thrombus formed with the metabolically active cells creates a different local
environment which is different compared to the bulk blood. Thus, misleading the sensor
6

from analyzing the actual condition of the analyte (i.e. bulk blood). Additionally, there will
reduced blood flow to the implanted area i.e. vasoconstriction which will change the local
form a consolidated structure around the implant which can entrap circulating cells. Thus,
aggregated platelets, cells and fibrin thread forms a thrombus known as blood clot. Shown
in Figure 1.3
Breaking of the thrombus and fragments freely entering the circulating blood poses a
serious threat. Thrombus once circulating freely into the blood stream can block any artery
or vein leading to a blood clot, hence it is as serious threat. Only presence of a monolayer
of thrombus will not affect the sensor or make it less responsive to the analyte. However,
thrombus formed with the metabolically active cells creates a different local environment
which is different compared to the bulk blood. Thus, misleading the sensor to from
analyzing the actual condition of the analyte (i.e. bulk blood). Additionally, there will
reduced blood flow to the implanted area i.e. vasoconstriction which will change the local
metabolic activity, thus affecting the sensor data even further by misinterpreting the
condition. It is clear that understating this coagulation cascade and stopping it in its
pathway is extremely important for full functionality of the sensor

Figure 1.2 Intrinsic Coagulation cascade initiated by blood contact with foreign materials
implanted within the vasculature. Dotted lines show potential pathways of positive
7

feedback mechanism. Typical end product of cascade is the formation of a thrombus on
the exposed surface of the implant. Adapted from Dee [17]
Form a consolidated structure around the implant which can entrap circulating
cells.
Thus, aggregated platelets, cells and fibrin thread forms a thrombus known as
blood clot. Shown in Figure 1.3

Figure 1.3 Depiction of exposed surface of an implanted sensor in contact with the blood.
Protein adhesion facilitates platelet adhesion and activation which initiates intrinsic
coagulation cascade leading to the thrombus formation. Adapted from Frost [5]
CONTROL POINTS IN COAGULATION CASCADE
•

Coagulation cascade is a complex system with both feedback and feedforward loop.
Controlling this complex process can eventually yield us control over implantable
sensor functionality and improving the lifetime of the sensor. Steps within the cascade
which are vital to the process are listed below (Adapted from Tissue-Biomaterials
Interactions. 2002: John Wiley &Sons [17])

•

Calcium: - Calcium is required at each step of the coagulation cascade, except for the
factor XII and XI activation. Without calcium blood with not clot.

•

Thrombin: - Thrombin is major component of the feedback loop, controlling the
availability of thrombin and its reactivity a major portion of the cascade can be
controlled

•

Clotting factors: - Clotting factors are the key to the coagulation cascade. Controlling
few clotting factors like Factor X can yield a potential control point because it is a
common link between the pathways.
8

•

Platelets contribution: - Platelets can be viewed as a surface catalyst for coagulation
process. Platelets are the first thing to adhere to the foreign body, initiating platelet
aggregation.

1.2.2 EXTRINIC COAGULATION CASCADE
Activated factor Xa is the site at which the intrinsic and extrinsic coagulation
cascades converge. The extrinsic pathway is initiated at the site of injury in response to the
release of tissue factor (factor III) and thus, is also known as the tissue factor pathway.
Tissue factor is a cofactor in the factor VIIa-catalyzed activation of factor X. Factor VIIa,
a gla residue containing serine protease, cleaves factor X to factor Xa in a manner identical
to that of factor IXa of the intrinsic pathway. The activation of factor VII occurs through
the action of thrombin or factor Xa. The ability of factor Xa to activate factor VII creates
a link between the intrinsic and extrinsic pathways. An additional link between the two
pathways exists through the ability of tissue factor and factor VIIa to activate factor IX.
The formation of complex between factor VIIa and tissue factor is believed to be a principal
step in the overall clotting cascade. Evidence for this stems from the fact that persons with
hereditary deficiencies in the components of the contact phase of the intrinsic pathway do
not exhibit clotting problems. A major mechanism for the inhibition of the extrinsic
pathway occurs at the tissue factor-factor VIIa-Ca2+-Xa complex. The protein, lipoproteinassociated coagulation inhibitor, LACI specifically binds to this complex. LACI is also
referred to as extrinsic pathway inhibitor, EPI or tissue factor pathway inhibitor, TFPI and
was formerly named anticonvertin. LACI is composed of 3 tandem protease inhibitor
domains. Domain 1 binds to factor Xa and domain 2 binds to factor VIIa only in the
presence of factor Xa.

9

Figure 1.4 the extrinsic coagulation pathway. Reaction products are underlined; the
dashed lines denote potential feedback loops. After the production of thrombin has been
achieved, the reactions outlined in

1.3 COPING UP WITH HOST COAGULATION RESPONSE
The most common method to prevent coagulation in patients with implanted
devices is the use of anticoagulants. The most widely used anticoagulant is heparin.
Heparin inactivates thrombi in the clotting process, this stops the formation of fibrin hence
prevent blood clot. Heparin is also used to treat blood clots formed abnormally inside the
blood vessel. Heparin is administrated both orally and intravascularly. Heparin interacts
with antithrombin III and enhances its ability to inactive coagulation enzyme thrombin,
which in turn prevents blood clot formations. It also affects other clotting factors like
Factor Xa and IXa [18]. However, heparin may have several negative effects. Heparin can
cause you to have bleeding episodes while you are using it and even several weeks after
you stop using it. It also interacts with a number of plasma proteins which are not even
involved in the coagulation cascade.
Studies have shown that plasma protein available for interaction with heparin may
vary from person to person [19], thus heparin is only partially effective at inhibiting the
thrombus formation on the implanted device. Moreover, prolonged used of heparin can
cause bleeding issues, for few weeks after the use. Extreme effects of heparin
administration are bone loss by decreasing bone formation i.e. osteoporosis and reducing
the platelet count [20] i.e. thrombocytopenia [21]. Many patients who have implanted
10

sensors in their body already have hemostatically compromised condition, using heparin
may worsen their condition. Hence. the use of heparin to improve the biocompatibility is
still under question.
It is clear that we cannot rely on the efficiency of the anticoagulants, there is a need
for development of new techniques for passivating the host response. Techniques like
development of polymer coating or outer membrane that could potentially passivate the
implanted device to some extent of the host response. Number of approaches like naturally
derived materials, diamond like carbon, hydrogels, topology treatments etc. were used [22].
Many of these materials showed good progress during in vitro study of cell or protein
adhesion, but in vivo study some resistance to host response. Ultimately, body’s defense
will overcome the static surface and initiate a host response which will affect the sensor
performance.

1.4 SOLUTION TO OVERCOME FOREIGN BODY RESPONSE
Properties of biomaterial surface influences how it will react with proteins once it
comes in contact with the blood. Blood comprises of about 150 different type of proteins.
Surface properties is usually grouped into three categories: geometric, chemical, and
electrical. Thumb rule being greater the surface area more possible sites for protein
interaction. For example, surface with grooves and pores will have greater surface are
compared to smooth surfaces. So, grooves and pores should be avoided unless they are a
part of the design. Also, surface features like the machine marks also provide additional
site for protein interaction. So, the key is keeping the implant surface as simple as possible.
Chemical composition of the material will determine which functional species are
available for interaction with biomolecules. The oxidized (passivated) surface of a metallic
biomaterial exposes metal and oxygen ions. Similarly, ceramic, and some glass, surfaces
comprise metal and nonmetal ions. A variety of functional species, such as amino,
carbonyl, carboxyl, and aromatic groups, can be present on the surface of polymeric
biomaterials. Depending on which species are exposed, biomolecules (or even particular
regions of the molecule) may have different affinities for various surfaces. For example,
hydrophobic surfaces tend to bind more protein as well as binding it more tenaciously.
Biomaterial surfaces are often in homogeneous. Patches, or domains, of different
functionality can exist on biomaterial surfaces, and these patches can interact differently
with biomolecules. For example, many metallic biomaterials contain at least two different
phases, such as the a- and b-phases in Ti-6Al-4V. Not only can the different phases behave
differently when interacting with biomolecules, but grain boundaries behave differently
than do grain interiors. In polymers, segregation resulting from folding of macromolecular
chains can give microstructural domains. Depending on the chemical species present
within the various domains, proteins will have different affinities for the patches.
Controlling this initial protein interaction on the surface of biomaterial can help
dictate the entire foreign body response.
11

To overcome the limited in vivo functionality and longevity of implantable devices,
some important approaches have been reported

1.4.1 BIOCOMPATIBLE MATERIAL COATING
The use of biocompatible materials for coating implantable devices is based on their
ability to mask the underlying surface. Masking is achieved by producing a hydrophilic
interface between the device surface and the tissue fluids, thereby minimizing tissue
reactions induced by device implantation [23]. The formation of these biocompatible layers
improves implantable device/host tissue interactions and consequently improves device
functionality and life span
Various natural, synthetic, and semisynthetic materials are currently utilized in the
fabrication of implantable device coatings. Naturally occurring materials include (a)
alginate, (b) chitosan, (c) collagen, (d) dextran, and (e) hyaluronan. These methods offer
the advantage of being very similar to macromolecular substances that the biological
environment is prepared to recognize and to deal with metabolically. On the other hand,
serious disadvantages are (a) natural polymers are frequently immunogenic, (b) these
polymers typically decompose or undergo pyrolytic modification at temperatures below
their melting point, thereby precluding the convenience of high-temperature thermoplastic
processing methods (such as melt extrusion) during the manufacturing of the implant, and
(c) since they are derived from animal or plant sources, natural variability in
macromolecular structure are expected. Numerous synthetic polymeric materials have been
employed as coating materials, e.g., poly(lactic-acid) and poly (lactic co-glycolic acid)
(PLGA) , poly(ethylene-glycol), 2-hydroxyethyl methacrylate , poly(ethylene glycol)
(PEG) , and poly(vinyl-alcohol) (PVA). Knowledge of the physical and chemical
properties of the polymer is a useful tool to rationalize the choice of the coating material.
Quinin and et al developed [24] Photo-crosslinked copolymers of 2-hydroxyethyl
methacrylate, poly (ethylene glycol) tetra-acrylate and ethylene dimethacrylate for
improving biocompatibility of biosensors. They coated the copolymer created on the
electrode of a glucose sensor and compared with a control electrode which did not have
any copolymer coating. The explanted samples were evaluated using scanning electron
microscopy. The control electrodes were highly encapsulated with fibrous material, while
the copolymer-treated electrodes induced much less encapsulation. The results show this
copolymer to be a candidate as a biocompatible coating for electrically wired
oxidoreductase-based subcutaneous biosensors.

1.4.2 ANGIOGENIC DRUGS
Biosensor functionality and longevity can be compromised by a biofouling
response and the formation of an avascular fibrous capsule around the device that greatly
decreases both the transport of analyte from the tissue to the sensor and the diffusion of
reaction products from the sensor to surrounding. Therefore, controlling fibrotic
encapsulation at the implant site would appear to be critical to achieve a functional and
extended life-time biosensor in vivo. One approach to improve the analyte transport around
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the implant is the promotion of angiogenesis. This can be achieved by inducing new blood
vessel formation in the vicinity of the sensor using growth factors such as the vascular
endothelial growth factor (VEGF) [25]. It is noteworthy that well-vascularized tissue at the
implant site is also critical for healing the trauma caused during implantation. Another
issue associated with the use of corticosteroid drugs to treat the inflammation process is
that these drugs also downregulate endogenous VEGF, thereby inhibiting angiogenesis.
Accordingly, a two-pronged approach (control of inflammation and induction of
angiogenesis) may be necessary.
Patil SD and et al developed [26] Dexamethasone-loaded poly(lactic-co-glycolic)
acid microspheres/poly (vinyl alcohol) hydrogel composite coatings for inflammation
control. Dexamethasone-loaded PLGA microspheres were prepared using a solvent
evaporation technique. Composites were fabricated by dispersing microspheres in PVA
solution and performing freeze-thaw cycling. Composites were implanted into
subcutaneous tissue of rats. PLGA microsphere/PVA hydrogel composites eluting
dexamethasone were successful in controlling negative tissue reactions at the sensortissue
interface by reducing the level of inflammation-mediation cells to those observed in normal
tissue.

1.4.3 IMPLANTED POLYMERS
Recent studies showed that active approach is much more effective than coated
materials developed in the past. Worked done earlier on surface bound heparin [27] has
been extended to materials which release heparin in vivo. Gutowaska et al. [28]. Developed
thermosensitive
polymer
blends
using
Biomer/poly
(Nisopropylacrylamide)/[poly(NiPAAm)]. This technique was based on temperature
dependent swelling of the material. At room temperature, i.e., below the lower critical
solution temperature (LCST) of poly (NiPAAm), the Biomer/(poly(NiPAAm) coatings are
highly swollen. Swelling enables fast loading of hydrophilic macromolecules (e.g.,
heparin) into the coating by a solution sorption technique. At a body temperature, i.e.,
above the LCST of poly (NiPAAm) the coatings are in a de-swollen state and the absorbed
macromolecules may be slowly released from a dense coating via a diffusion controlled
mechanism. The results show that the heparin release from
Biomer/poly(NiPAAm)-coated surfaces resulted in a significant reduction of thrombus
formation on test surfaces in contact with venous blood as compared to control surfaces in
vitro studies. However, considering the complexity of the in vivo environment, there is
need for further study to access the efficacy of heparin releasing materials in improving the
biocompatibility of the implanted sensors.
Nitric Oxide (NO) is another potentially viable option to help control the coagulation
cascade.NO has a diverse array of functions in vivo including help controlling the blood
vessel tone and adhesion molecule expression. Nitric Oxide is also a potent inhibitor of
platelet aggregation and activation [22,23], due to its role in stimulation calcium
sequestration and inhibiting the synthesis of thromboxane A2 in platelet. NO is also
involved in endothelium cell and smooth muscle cell proliferation; it has a direct role in
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destruction of bacteria during phagocytosis by macrophages [24]. Vascular endothelium
cells generate NO flux of 1.0-4.0*10-10 mol/cm2 min continuously [25]) has been their
primary basis for the non-thrombogenic properties of the vascular endothelium, surface
which elicits no host response despite constant contact with precursor molecules to the
intrinsic coagulation cascade. Endogenous NO supply diffuses into the lumen of the blood
vessels and smooth muscles cells that surrounds all the arteries where it plays an important
role in preventing platelet activation in healthy blood vessels.
The innate physiological function of NO makes it a strong candidate for improving the
biocompatibility of the implanted sensors. NO releasing sensors will be single handed
capable of controlling the both platelet adhesion and activation along with minimizing
vasocontraction. NO releasing subcutaneous implanted sensors will ensure increased blood
flow to the sensor surface, increasing transfer of analyte and reducing bacterial infection.
Half-life of NO in blood is 0.5-1.8ms [23], thus the NO generated will no create any
systemic effects.

1.5 NO RELEASING MATERIALS
The encouraging work in early NO studies led to serious efforts for creating NO
releasing materials which has been ongoing for 20 years. Organic nitrites, metal complexes,
nitrosamines, nitrosothiols and diazeniumdiolates are some of the potential candidates
arising from the work. The diverse structures used for NO donors causes varied chemical
reactions and NO-release kinetics [26], which can be used for controlling the dose of NO
delivered.
There are two mechanisms from which NO can be generated from their donors, 1)
exogenous NO release and 2) those which generate NO by decomposing endogenous NO
donors.

1.6 EXOGENOUS NO DONORS
Recently a class of NO donor’s diazeniumdiolates has getting much attention
known as N-diazeniumdiolates, or “NONOates” as an exogenous NO donor. They produce
predictable amount of NO and ease to prepare. NONOates generate NO spontaneously
under physiological condition and stable at ambient temperature and can be covalently
attached to polymer films [28,29]. Release of NO from NONOates is influenced by
biological factors so no tolerance can be developed against it. The stability of Ndiazeniumdiolates depends on the concentration of the donor in material as well as pH
temperature and/or structure of substrate. Study by Frost et al. [30] studied the performance
of a Clarke-style amperometric oxygen-sensing catheter coated with a ~ 100µm layer of
polymer covalently bonded to diazeniumdiolates. Results suggested that NO release
through this technique greatly reduces thrombus formation.
RSNOs also known as S-nitrosothilos emerged as a potential candidate for exogenous NO
release. There are three known mechanisms for NO generation from RSNOs: •

Metal ion i.e. copper mediated decomposition
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•

Ascorbate mediated decomposition

•

Photo-initiated decomposition [31]

Light can be used as an ON/OFF switch to generate NO if decomposition via metal
ions. Ascorbate mechanism is independent of light. Frost et al. developed a tri-layer silicon
rubber (SR) film wherein one of the layer is blended with S-Nitroso-N-acetylDLpenicillamine derivatized fumed silica was sandwiched between two layers of pure SR.
Film showed photolytic NO generation without being sensitive to copper and ascorbate.
NO generated was dependent on the intensity and duration of light it was exposed to. This
points out that RSNOs with the help of a controllable light source could be used to anchor
the NO generation on the surface of the implantable sensor.

1.7 ENDOGENEOUS NO DONORS
NO is generated naturally in mammalian body, NO precursors in the form of nitrites
and RSNOs are present in the body in micro-molar concentration. Cu2+ metal ions along
with other metals are known to cause reduce RSNOs to generate NO in aqueous solution
[32]. Wu et al. developed polymeric coating with Cu0 particles which will slowly corrode
to produce reactive ions to decompose RSNOs to produce NO [34]. These coatings were
applied to catheters and tested in vivo showed positive results. However, few incidences
showed that control and NO generating fiber showed thrombus formation, because of the
low concentration of RSNOs in those animals.
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Figure 1.5 Clarke type amperometry intravascular sensor post-explanation. The region to
the left with dotted lines shows the portion of the sensor which was placed within the
vasculature. The sensor on the left incorporated NO releasing material sensor on the right
was without modification

1.8 BACKGROUND OF ASCORBIC ACID
Ascorbic acid is an isolated nutrient which is part of vitamin C. Ascorbic acid can be
normally found in human body. Recently studies on ascorbic acid has been increasing
because of its ability to react with RSNOs and produce NO. Holmes et al. reported that
ascorbic acid can interact directly with RSNOs if present in more than milli-molar
concentration to produce NO. Preliminary evidence suggested that it is a decomposition
product of ascorbate responsible foR the NO from nitrosotiols rather than high
concentration of ascorbate. Higher concentration is required because the species
responsible for the decomposition is not actually ascorbate. A partial decomposition
pathway can be seen in Figure 4.
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Frost and et.al. used S-Nitroso-N-acetyl-DL-penicillamine (SNAP) as NO donor and
treated with both fresh ascorbate and decomposed ascorbate. Nitric oxide measured using
via chemiluminescence using nitric oxide analyzer. Ascorbate was allowed to decompose
naturally under ambient condition for 8 days. It showed that oxidized ascorbate releases 10
times more NO than the fresh ascorbate. Seen in Figure 5. This shows clear evidence that
it is actually a decomposition product of ascorbate than the ascorbate itself.
Depending on the decomposition pathway (Figure 4) they suspected the compound to
be a four-carbon sugar Threose. They treated threose with SNAP to measure the amount
of NO release. Results showed that only 50% of the threose was used, which states that
clearly there is another decomposition product present in threose syrup which is
responsible for NO release. Clearly a lot of work has to be done in identifying the actual
product that causing it to release NO.

1.9 STATEMENT OF PURPOSE
The extent to which host response can be controlled is directly proportional to the
functionality of the implanted device. Controlled NO release from the implanted device is
the key. Given that it is now know how different fluxes of NO generated will impact the
host response at the tissue -material interface in the acute and chronic response, it cannot
be known the best way to mitigate the host response using NO. Determining an ideal
therapeutic flux of NO and then being able to deliver the needed amount will help fight
against the host response tremendously.
Natural source of reducing agent along with naturally available NO donors could be
instrumental in developing a new technique for NO release. Ascorbic acid is naturally
present in human body and traces of S-nitrosoglutathione is been found in the form of
proteins. The goal of this work is to identification of NO generating decomposition product
of ascorbic acid. High performance Liquid Chromatography (HPLC) along with
chemiluminescence (NO Analyzer) can be used for separating compound from
decomposed ascorbate and measuring NO generated from it. Once the compounds are
separated Mass Spectroscopy can be used to identify the compound.
To collect real time NO data from the HPLC separated compounds we need a
device which is capable of providing a medium for the compounds to react and generate
NO. A new 3-D printed device needed to be created for integrating HPLC with NO analyzer
(Discussed in detail in chapter 2). Thus a 3-D printed device is able to serve as a medium
for HPLC separated compound to react with RSNOs to generate NO.
If the active compound identified is non-toxic and can be stabilized, it could prove as
a novel method too initial RSNOs decomposition in polymeric material or endogenously
from RSNOs present in the body. E.g. Medical grade polyurethane doped with the reducing
agent can be formulated in such a way that when it comes in contact with the blood the
active agent leaches from the material decomposing circulating nitrosothiols.
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Figure 1.6 Decomposition pathway of ascorbic acid to the reducing sugar threose in neutral
pH
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Figure 1.7 Final concentration of oxidized ascorbate and fresh ascorbate were 2.5 mM after
the first inject and 5.0 mM after the second injection.
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2. ASCORBIC ACID
Ascorbic acid or vitamin C is a small molecule nutrient that is essential for normal
functioning in the human body (see Figure 2.1). Among its many functions, it acts as an
antiscorbutic agent (curing scurvy) and is a cofactor in a variety of enzymatic process [1].
Ascorbic acid is also known for its antioxidant property in both in vitro and in vivo. The
first metabolic decomposition product of ascorbic acid is its conversion to dehydroascorbic
acid (DHA); this process is reversible which is suspected to be responsible for antioxidant
properties of ascorbic acid. DHA will irreversibly degraded to 2,3-diketogulonic acid and
then to over 50 species containing five or fewer carbons [2]. The complete pathway of
degradation is yet unknown. Ascorbic acid is also known to react with RSNOs to produce
NO [3]. Much work has been done on studying degradation products of ascorbic acid and
their functions in the body, but this complex pathway is far from being understood. Gaston
Vernin, et al. studied thermal degradation of ascorbic acid at 3000 C yielded furan
derivatives and ∝, 𝛽𝛽-unsaturated cyclic ketones with a fivemembered ring [4]. Since

ascorbic acid is a part of our daily food cycle it makes it all the more important to identify
its decomposition product triggering NO release, since it is naturally present in our body.

Figure 2.1 The structure of ascorbic acid.
There are three known mechanics of NO generation from S-nitrosothiols (RSNOs)
[5]. Copper mediated decomposition in which Cu2+ is first reduced to Cu+ and then Cu+
reduces RSNOs to NO and produces disulfide bonds. Common species used to reduce Cu2+
to Cu+ are free thiolate ions present and ascorbic acid. Ascorbic acid itself has been reported
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to directly interact with RSNOs when it is present at greater than millimolar concentrations
to reduce RSNO to NO and produce free thiol groups. The mechanism of this reaction is
not known [6]. The third known mechanism of NO generation from RSNOs is by means
of photoinitiation.
Dasgupta and Smith published a study entitled “Kinetics and Mechanism of the
Decomposition of S-Nitrosoglutathione (Type of RSNOs) by Ascorbic Acid and Copper
Ions” [6]. They state that S-nitrosothiols severs as a good source of NO mainly due to the
ease of cleavage of S-N bond which consequently produces NO. The reductive
decomposition of the specific RSNO, S-nitrosoglutathione (GSNO) by ascorbic acid
produced NO which was monitored both electrochemically and spectrophotometrically.
The rate of reaction and NO release occurs in both an ascorbate concentration and a pH
dependent manner. Where ascorbate is required in greater than millimolar levels and little
to no decomposition at low pH (below 5.5). Reductive decomposition of GSNO by
ascorbate in an aqueous solution was carried out in the presence of EDTA to suppress any
Cu2+ present.
Dasgupta and Smith proved that GSNO decomposed with a liner dependence on
the concentration of ascorbate from 10-55mM. In their analysis. They could only account
for the 90% of ascorbate used initially when combining total ascorbate and DHA present
initially, claiming that the lost 10% was probably due to “analytical error”. This suggests
that ascorbic acid decomposes into different or additional products and it is possible that
one of these products is an active agent that is responsible for the release of NO from
RSNOs. (i.e., more favorable redox potential and/or kinetics of electron transfer to react
directly with RSNOs).
Figure 2.2 shows NO generated from 0.227 mM SNAP solutions in PBS at pH 7.4
upon the addition of fresh ascorbate and the addition of the same amount of oxidized
ascorbate from the same solution after 8 d of decomposition under ambient conditions
using chemiluminescenc detection [7]. After the first injection of ascorbate or oxidized
ascorbate, the final concentration of ascorbate was 2.5 mM and 5 mM after the second
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injections. Clearly there is more NO generated from the oxidized ascorbate than from the
fresh ascorbate, by nearly a factor of 10

Figure 2.2 Comparison of NO generated from 0.227 mM SNAP solution in PBS at pH 7.4
[7].
None of the work published to date has been able to identify the mechanism of
ascorbic acid to directly decompose RSNOs nor have decomposition products of ascorbate
been investigated as potential species that release NO from them. Correctly identifying the
product or products that may be responsible for RSNO decomposition may provide us with
new candidate material(s) for coatings on the implanted device and may also improve their
performance in vivo and help mitigate host response. This study has developed a new
experimental method to help separate the decomposition products which are responsible
for NO release from the well-known RSNO, S-nitroso-Nacetylpenicillamine (SNAP).
As previously discussed in chapter 1 the amount of NO generated from
decomposed ascorbic acid is more than that produced by fresh ascorbic acid. This clearly
indicates that it is not actually ascorbic acid but one its decomposition product which leads
to increased production of NO.
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2.1 WORKFLOW OF THE EXPERIMENTS
The general idea is to provide clear evidence that one or more of the products in
decomposed ascorbic acid is capable of generating NO from a standard RSNO solution.
Fresh ascorbate was allowed to decompose and then the products were separated with
reversed-phase HPLC. UV-VIS spectroscopy of known standards of both ascorbic acid and
dehydroascorbic acid were used for determining peak absorption wavelength of these
compounds A diode array detector that recorded full UV-Vis spectra was used with the
HPLC system to achieve detection of the components present in the decomposed ascorbate
solution. Once peaks of the decomposed ascorbate were obtained along with the retention
time, spectral analysis was carried to track how the absorbance changes over time. This
helped further confirm the presence of more than one compound in decomposed ascorbic
acid. Once the separation was successful, the HPLC eluent was merged with a stream of
S-nitroso-N-actylpenicillamine (SNAP) and the headspace was sampled to detect the
production of NO. The compounds separated via HPLC that generated NO were then
analyzed with mass spectrometry to identify candidate compounds that are responsible for
NO generation.

2.2 MATERIALS AND METHODS
L- (+)-Ascorbic Acid used for experiments was purchased from J.T BAKER. 20 ml
disposable scintillation vials were used for storage of ascorbic acid samples; Deionized
water was used as base solvent for preparation of ascorbic acid. Ascorbic acid of varying
concentration was prepared ranging from 1 M to 100 mM depending upon the needs of
the experiments. Ascorbic acid was allowed to decompose naturally for 8 days under
ambient conditions in the presence of normal sunlight at pH 5.5, decomposed ascorbic acid
pH was measured to be 4.5. A PerkinEmler Lambda 35 UV/VIS Spectrometer was used to
read solution absorbances. Disposable spectrophotometer cuvettes purchased from VWR
International (Randor, PA) were used. A PerkinELmer HPLC systems consisted of Series
200 Vacuum Degasser, Series 200 pump, Series 200
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EP Diode Array Detector and a 20 L injection loopwas used. The column used for HPLC
separation was C18 (5 μm, 10 cm x 3.2 mm) purchased from ES Industries. C18 is
combination of hydrophobic and silanophilic mechanisms. C18 packings are highly
retentive for polar and non-polar compounds. Two mobile phase solvents were used:
Mobile Phase A – HPLC grade Methanol + 0.1% Trifluoroacetic acid, Mobile phase B –
Deionized water + 0.1% Trifluoroacetic acid.. Sievers 280i Nitric Oxide Analyzer was used
for the direct detection of NO via chemiluminecnce detection. The syringe pump used for
controlled release of RSNOs was purchased from Kent Scientific (Farmingdale, NY).

2.2.1 SNAP SYNTHESIS
N-Acetyl-DL-penicillamine, sodium nitrite (NaNO2) and methanol were obtained
from Sigma (St.Louis, MO). Sulfuric acid (H2SO4) and hydrochloric acid (HCl) were
obtained from Fisher Scientific (Pittsburgh, PA). SNAP crystals were made using the
method of Field,136 et. al [7]. One-hundred mg of N-acetyl-DL-penicillamine, 5 mL of 1
M NaNO2, 10 mL of methanol, 10 mL of 1 M HCl and 0.5 mL of H2SO4 were combined.

A very dark green solution developed nearly instantly. The solution was stirred for ~40
min. The volume of the solution was reduced by blowing nitrogen gas over the solution
and the flask was ice cooled. Green crystals were collected via suction filtration and
washed with water. Crystals were re-crystalized from methanol and allowed to air dry.

2.2.2 SNAP-PDMS SYNTHESIS
Detailed synthesis of this materials has been described elsewhere [7], briefly 1.6 g
of hydroxy-terminated PDMS was mixed with 0.3 g of 3-aminopropyl trimethoxysilane,
2.4 mg of dibutyltindilaurate and 8 mL of toluene. The solution was stirred for 24 h to
crosslink the PDMS. A self-protected thiolactone was synthesized according to the method
by Moynihan [8]. Fifty milligrams of this thiolactone was then mixed with 1 mL toluene
followed by 2 mL other crosslinked PDMS. The solution was stirred for an additional 24
h to allow the thiol-containing compound to react with the primary amine groups present
on the cross-linking agent. The resultant free thiol was then converted to the corresponding
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RSNO by reaction with t-butylnitrite, producing the characteristic emerald green SNAPPDMS.
All the experiments were carried out in two sets, first it was performed on fresh
ascorbic acid and then repeated on decomposed ascorbic acid. For verifying the
consistency of the results experiments was repeated at least three times. In-order to separate
the compounds using HPLC there was need to identify the wavelength window of fresh
and decomposed ascorbic acid. This wavelength window will help setup the detection limit
for both compounds while the separation is being performed. So the first setup is to identify
the absorption wavelength of both the compounds using UV-VIS spectroscopy.

2.2.3 UV-VIS SPECTROSCOPY
To establish the detection limit of the HPLC system toward ascorbic acid, UVVIS
Spectroscopy was used. UV-VIS Spectroscopy works on Beer-Lambert law. Ascorbic acid
and decomposed ascorbic acid sample was prepared and diluted to 1 micro-molar
concentration for accuracy. Since de-ionized water was used for preparation of both the
samples, it was used as a base sample for the experiment. Since the concentration of the
samples are known UV-VIS Spectroscopy helps to identify the absorption wavelength of
the samples.

2.2.4 NO ANALYZER
To integrate the complex system and get a real-time analysis of the amount of NO
released a medium was required. 3-D Printed device was developed to act as a medium to
integrate multiple system together details of the device are describe in detail in the latter
half of the chapter. Initially NO analyzer was used to track the amount of NO released
when fresh ascorbic acid and decomposed ascorbic acid when treated with SNAP using the
3-D Printed device. This data clearly indicates that decomposed ascorbic acid produces
more NO than fresh ascorbic acid. (Figure 2.11 provides sufficient evidence). Left and the
right opening of the 3-D printed device receives input from syringe pump i.e. SNAP and
Fresh/Decomposed ascorbic acid. Central opening is connected to the NO analyzer which
collected the NO reading data across the gas permeable membrane. Graph below represents
NO analyzer data.
28

Once HPLC is used for separation of decomposed ascorbic acid, NO analyzer is
used again to repeat the same procedure as above to track the amount of NO released. 3D
printed device receives one input from syringe pump i.e. SNAP and the other input from
HPLC i.e. separated compounds. This provides real time data and a direct comparison
which compound produces more NO.

2.3 RESULTS AND DISCUSSION
2.3.1 UV/VIS DATA
UV/VIS spectroscopy was performed on both fresh and decomposed ascorbic acid.
Ascorbic acid (1mM) and decomposed ascorbic acid (1mM) were diluted to 1 M

concentration for higher resolution and more accurate data. Since deionized water was used

as a base solvent for preparing both compounds, hence it was also used a standard reference
for both the experiments. Detection window for UV-VIS is between 200-700 nm
Figure 2.3 shows a representative UV/VIS spectrum for fresh ascorbic acid and
decomposed ascorbic acid. Data suggests that peak absorption wavelength of ascorbic acid
is 263nm which is consistent with the literature. Several peaks with consistent change of
absorbance can be seen in the figure. Additionally, the absorbance of the ascorbic acid peak
at 263nm is reduced in intensity from 0.56 to 0.25, indicating a loss of compound. This
confirms that the ascorbic acid did indeed decompose and other compounds are present in
the solution. These peaks range from 200 – 400 nm. This information is vital because it
will help setup up the detection range for HPLC while physically separating these
compounds.

29

Figure 2.3 UV/VIS data for fresh ascorbic acid sample and Decomposed ascorbic was
allowed to decompose in natural light and ambient temperature for 8 days, acid with 1
micro-molar concentration.

2.3.2 HPLC DATA
Because Figures 2.5 and 2.6 clearly indicate that some product in the decomposed
ascorbate solution is initiating release of NO, reversed phase HPLC was used to separation
the decomposed ascorbic acid in an effort to allow the identification of which component(s)
were responsible for this NO release. In this technique, the binary mobile phase (i.e. mobile
phase was polar and the C18 stationary phase was non-polar was used).
Elution conditions were optimized for both fresh and decomposed ascorbic acid.
Compounds once eluted and separated are detected by the Series 200 EP Diode Array
Detector. Optimized separation conditions are listed in table 2.1
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Table 2.1. Represents working condition for HPLC. Mobile phase A consists of Methanol
+ 0.001% trifluoracetic acid and mobile phase B consists of de-ionized water + 0.001%
trifluoracetic acid.
Parameters

Fresh ascorbic acid

Decomposed ascorbic acid

Solvent condition

Mobile Phase A 90% and Mobile Phase A 75% and
Mobile Phase B 10%
Mobile Phase B 25%

Flow Rate

1 ml/min

1 ml/min

Detection Range

200-300 nm

200-450 nm

Pressure

1000-1200 psi

1000-1200 psi

To make sure that mobile phase solvents are not interfering with the separation of
compound we also ran a blank compound i.e. Mobile phase A (Methanol + TFA) solvent
as a compound to be injected. Figure 6 represents HPLC data for blank sample.
Figure 2.4 shows that ascorbic acid is retained at time 1.407 minutes and no other
compound being eluted from fresh ascorbic acid sample. Figure 2.5 shows two peaks at
0.691 minutes and 1.198 minutes which surely suggests presence of more than one
compound in decomposed ascorbic acid sample. A UV-Spectrum analysis was carried out
on the two peaks obtained (seen in Figure 2.6) shows how the absorbance for the peaks
changes over time.
Figure 2.6 shows that for the first peak absorbance is 0.05 and gradually changes
as the peak descend and when the second peak ascends, the absorbance is 0.16 indicating
a different compound and it reaches to 0.2 when the peak descend; Once again providing
a clear evidence of presence of more than one compound.
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Figure 2.4. HPLC for fresh ascorbic acid sample represents the elution time of the sample
along with the absorbance. Concentration of fresh ascorbate used was 100 mm. 50µL of
the sample was injected.
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Figure 2.5. HPLC for decomposed ascorbic acid sample. Represents the elution time of the
sample along with the absorbance. Concentration of decomposed ascorbate used was 100
mm. 50µL of the sample was injected.
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X axis: - Time in minutes
Y axis: - Absorbance

X axis: - Time in minutes
Y axis: - Absorbance

Figure 2.6. UV-SPECTRUM of the peaks obtained from decomposed ascorbic acid.
Absorbance changes for the two peaks. From 0.06 for the first peak to 0.2 for the second
peak. Indicating two different compounds.
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Figure 2.7. HPLC for blank sample. Shows no compound coming out of the HPLC system.
Indicating Mobile phase solvents do not interfere with the separation of decomposed
ascorbic acid.

2.4 3-D PRINTED DEVICE
2.4.1 NEED FOR THE DEVICE
In order to identify which component(s) in these 2 solutions (fresh and decomposed
ascorbic acid) was responsible for initiating NO release from SNAP, a novel device was
designed and used to couple the separation capacity of the HPLC with the direct NO
measurement capability of chemiluminescence. Much of the earlier work done in the
literature are just techniques used to separate compounds from decomposed ascorbic acid
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and identify them. None of the work done to this point directly studied which of these
compounds are responsible for NO release when in contact with RSNOs.

2.4.2 SPECIFICATION OF THE DEVICE
Device was printed by Dr. Joshua Pearce using an open source method of scientific
hardware design [Pearce 2012; Pearce 2014; Baden 2015] [8] The main apparatus was
augmented with a 3-D Printed Complex-Carbohydrate-Mixer, first developed by Brian
Swanson and made available on Github [Swanson, 2014]. [9,10]. This device facilitates
NO detection by allowing the compounds to mix and react with the small mixing chamber
located at the center of the device. Released gases are detected by allowing them to pass
through a filter which is a gas permeable membrane. The membrane is placed between the
device and the 3-D printed cover, allowing the sampling of any NO generated when the
eluent from the HPLC mixes with the stream of RSNO via chemiluminescence. Figure 2.10
represents the 3-D printed device.

Right
Opening
Left
Opening

B

A

Figure 2.8 CAD Design of the 3-D printed device.
A: - Represents the actual device, left opening takes input from the syringe pump and right
opening takes input from HPLC.
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B: - Represents the cover of the Meshlab screen shot of STL of 3-D printed cover with
mounting holes
The 3-D printed parts can be manufactured in any fused filament fabrication (FFF) based
3-D printer such as the open source RepRaps (self-replicating rapid prototypers)
[Bowyer; Sells; Jones] [11,12,13]. The custom parts are 3-D printed in polylactic acid
(PLA) or similar hard thermoplastic, which is chemically stable with the experiment. In
this case, natural PLA was printed at 100% infill with 100 micron layers. Previous work
that investigated the mechanical properties of PLA has found that these materials are
optimal for strength [Tymrak; Wittbrodt] while also minimizing contamination from
unknown pigments in commercial 3-D printing filament.
NO generated passes Through

SNAP
injected

the Central Opening and it
serves as an input to the NO
analyzer
Small reaction chamber
where SNAP
Decomposed/Fresh
ascorbic acid sample to
release NO

Decomposed/Fresh
ic acid through
Ascorb
HPLC

Figure 2.9 represents schematic flow of compounds for 3-D printed device.

2.4.3 VALIDATING THE DEVICE
To validate proper functionality of the device, experiments were performed that
directly injected solutions of a known RSNO and known samples of agents that would
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initiate NO release from the RSNO solution. Fresh 100mM ascorbic sample and SNAP
were injected through the two openings on the left and the right side of the 3-D printed
device using a syringe pump. Flow rate was set at 1ml/min. NO Analyzer input was
connected to the Central opening on the 3-D printed plate placed above the gas permeable
membrane. Figure 2.10 shows NO Release Profile of the fresh ascorbic acid sample. To
setup a detection limit for the system this experiment was repeated 3 times with varying
concentration of SNAP starting from 1mg and going down to 0.2mg (i.e. 1mg/50ml of deionized water). Table 2.2 represents the compound of NO released by each sample.
Table 2.2 Total amount of NO released by each sample.
Samples

Concentration

Amount of NO released

S1

1mg SNAP + 100mm

4.07x10-9 moles

Ascorbic acid
S2

0.5mg SNAP + 100mm

2.33x10-9 moles

Ascorbic acid
S3

0.2mg SNAP + 100mm
Ascorbic acid
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6.62x10-11 moles

NO Profile
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Figure 2.10 Represents NO release profile of Samples S1, S2 & S3
The second part of the experiment, samples of 100mM decomposed ascorbic acid
and SNAP (0.5mg/50ml of di-ionized water) were injected through the two openings.
Decomposed ascorbic acid was obtained by allowing fresh ascorbic acid sample to
decompose in ambient conditions for eight days. The NO analyzer input was connected to
the central opening on the 3-D printed plate placed above the gas permeable membrane.
Figure 2.11 shows the NO release profile of the decomposed ascorbic acid sample.
It can be clearly seen from the data that decomposed ascorbic acid releases twice
the amount of NO compared to fresh ascorbic acid sample. Thus, validating that device can
be used to integrate HPLC system directly with the NO analyzer. The difference will be
that one of the inputs is from the HPLC system and the other using Syringe pump, instead
of both coming from syringe pump as in case of the above experiments.
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2.5 HPLC INTEGRATED WITH NO ANALYZER
Once the compounds had been separated via HPLC, the next task was to integrate it with
the chemiluminecscne detector for NO with the system to prove that decomposed ascorbic
acid generates more NO than fresh ascorbic acid. To integrate the two systems, we use the
device 3-D Printed Device. Figure 2.11 shows a schematic representation of the integrated
system.
Workflow of the setup is simple: waste coming out of the HPLC acts as one of the inputs
for the bridge and the second input is SNAP which acts as an NO donor. The two
compounds are allowed to react at the center of the “3-DPrinted Device”. A gas permeable
membrane is placed over the central opening which is directly connected to the NO
Analyzer. Waste from the reaction is collected into an empty vial. There is a Lag time
between the compounds reaching the BRIDGE and the NO Generated.

Figure 2.11 Schematic flow of the integrated system. Two inputs to the 3-D Printed device
are from HPLC and syringe pump. NO Analyzer data is collected through an opening
across the gas permeable membrane
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Figures 2.12 Represent the amount of NO Released from the blank sample, Fresh and
decomposed ascorbic acid. Spike in the NO profile for blank sample is due to the SNAP
alone and lag time in HPLC compound reaching the 3-D Printed Device. The amount of
NO released from the decomposed ascorbic acid is more than twice the amount released
from fresh ascorbic acid. This proves that when ascorbic acid decomposes it release more
NO than fresh ascorbic acid, which concludes that a new compound is formed when
ascorbic acid decomposes.

Table 2.3 Represents Total NO released by blank sample, fresh and decomposed ascorbic
acid
Compounds

Total NO released ±(SD)

Fresh ascorbic acid

170x10-12 (1.07x10-10) moles

Decomposed ascorbic acid

350x10-12 (3.50x10-10) moles

Blank sample

6.29x10-12 (6.29x10-12) moles
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Figure 2.12 NO release profile for blank sample, fresh and decomposed ascorbic acid.

2.6 CONCLUSION
UV-VIS Spectroscopy was used to identify the absorption wavelength of fresh and
decomposed ascorbic acid. Once the detection wavelength was established it was used to
setup a wavelength window for separation of decomposed ascorbic acid. HPLC separation
technique helped to separate decomposed& fresh ascorbic acid.
Figure 2.5 shows the separation of decomposed ascorbic acid with retention time.
Change in the absorbance from the UV-Spectra graph represents presence of more than
one compound present. Once the separation was complete NO data was collected for both
decomposed and fresh ascorbic acid by using 3-D Printed device as a medium to integrate
HPLC with NO analyzer to obtain real time data.
Figure 2.12 represents the amount of NO released from decomposed ascorbic acid
when it was separated using HPLC. Same procedure was also repeated using a blank, which
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proves that it is actually decomposed ascorbic acid that causes more NO to be released as
compared to Fresh ascorbic acid. The amount of NO released by decomposed ascorbic acid
is almost twice the amount released by fresh ascorbic acid.
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3. IDENTIFICATION OF NO RELEASING COMPOUND
Ascorbic acid is a well-known antioxidant and vitamin which is widely distributed
in nature, and also part of our daily diet. Ascorbic acid is also known for its antioxidant
property in both in vitro and in vivo. The initial step in ascorbic acid metabolism is
conversion into dehydroascorbic acid (DHA); this process is reversible and is suspected to
be responsible for its antioxidant properties. DHA is degraded to 2,3diketogulonic acid and
then to over 50 species containing five or less carbons [2]. The complete mechanism of
degradation is unknown due to the highly reactive and complex pathways available for
decomposition [2]. Ascorbic acid is also known to react with RSNOs to produce NO. Much
work has been done on studying degradation products of ascorbic acid, but the mechanism
of decomposition under physiological conditions has not been elucidated. Gaston Vernin,
et al. studied thermal degradation of ascorbic acid at 3000 C yielded furan derivatives and
, β-unsaturated cyclic ketones with a fivemembered ring. Since ascorbic acid is a required
part of our daily food cycle it makes it all the more important to identify its decomposition
product(s) triggering NO release, since it is naturally present in our body.
There are three known mechanics of NO generation from S-nitrosothiols (RSNOs)
[3]. Copper mediated decomposition in which Cu2+ is first reduced to Cu+ and then Cu+
reduces RSNOs to NO and produces disulfide bonds. Common species used to reduce Cu2+
to Cu+ are free thiolate ions and ascorbic acid. Ascorbic acid itself has been reported to
directly interact with RSNOs when it is present at greater than millimolar concentrations
to reduce RSNO to NO and produce free thiol groups. The mechanism of this reaction is
not known [4]. The third known mechanism of NO generation from RSNOs is by means
of photoinitiation.
Dasgupta and Smith published a study entitled “Kinetics and Mechanism of the
Decomposition of S-Nitrosoglutathione (Type of RSNOs) by Ascorbic Acid and Copper
Ions” [6]. The state that S-nitrosothiols severs as a good source of NO mainly due to the
ease of cleavage of S-N bond which consequently produces NO. The reductive
decomposition of the specific RSNO, S-nitrosoglutathione (GSNO) by ascorbic acid
produced NO which was monitored both electrochemically and spectrophotometrically.
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The rate of reaction and NO release occurs in an ascorbate concentration and pH dependent
manner. There is little to no reaction at low pH (below 5.5). Reductive decomposition of
GSNO by ascorbate in an aqueous solution was carried out in the presence of EDTA to
suppress any copper catalysis.
Dasgupta and Smith proved that GSNO decomposition had a liner dependence on
the concentration of ascorbate from 10-55mM. In their analysis. they could only account
for the 90% of ascorbate used initially when combining total ascorbate and DHA present
initially, claiming that the lost 10% was probably due to “analytical error”. This suggests
that ascorbic acid decomposes into different or additional products and it is possible that
one of these products is an active agent that is responsible for the release of NO from
RSNOs. (i.e., more favorable redox potential and/or kinetics of electron transfer to react
directly with RSNO).

Figure 3.1 Comparison of NO generated from 0.227Mm SNAP solution in PBS at Ph 7.4
[5].
Figure 3.1 shows NO generated from 0.227 mM SNAP solutions in PBS at pH 7.4
upon the addition of fresh ascorbate and the addition of the same amount of oxidized
ascorbate from the same solution after 8 d of decomposition under ambient conditions
using chemiluminescenc detection. After the first injection of ascorbate or oxidized
ascorbate, the final concentration of ascorbate was 2.5 mM and 5 mM after the second
injections. Clearly there is more NO generated from the oxidized ascorbate than from the
fresh ascorbate, by nearly a factor of 10.
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None of the work published to date has been able to identify the mechanism of
ascorbic acid to directly decompose RSNOs nor have decomposition products of ascorbate
been investigated as potential species that release NO. Correctly identifying the product or
products that may be responsible for RSNO decomposition may provide us with new
candidate material(s) for coatings on the implanted device and may also improve their
performance in vivo and help mitigate host response. This study has developed a new
experimental method to help separate the decomposition products which are responsible
for NO release.
As previously discussed in chapter 1 the amount of NO generated from
decomposed ascorbic acid is more than that produced by fresh ascorbic acid. This clearly
indicates that it is not actually ascorbic acid but one its decomposition product which leads
to increased production of NO.
Ascorbic acid upon oxidation is converted into dehydro-L-ascorbic acid (DHA),
which later is non-enzymatically converted to a variety of products [2]. These products are
known as ascorbic cascade. We used high performance liquid chromatography (HPLC)
with a photo diode array detector (PDA) along with Series 400 quaternary pump to separate
the decomposed ascorbic acid. As concluded in Chapter 2 we did separate compounds from
decomposed ascorbic acid and integrated it in real time with NO analyzer using the “3-D
Printed device”. We concluded from the results that it is not actually ascorbic acid but one
of the decomposition products of ascorbic acid that produces NO from RSNOs. Although
HPLC separated some of the components of the complex mixture that resulted from the
decomposition of ascorbic acid, the component(s) that eluted at 1.98 mins (Figure 2.7,
Chapter 2) that cause release of NO need to be identified. There for MS analysis of this
peak was carried out using a Thermo Finnigan LCQ Advantage Ion-Trap was the device
used to run the Mass spectroscopy analysis.
As stated in chapter 2, HPLC was carried out using PDA detector and series 400
pump. Separation was achieved using C18 column. Mobile phase was methanol and
deionized water each containing 0.01% trifluoracetic acid. Eluent was pumped at the flow
rate of 1ml/min. The chromatographic data i.e. retention time, wavelength, absorbance was
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obtained as contour maps through multichannel PDA detector, which covered a wavelength
range of 200-450 nm. Elutes were examined by absorption spectrum, further
characterization and identification of the compounds were done using Electron Spray
Ionization technique was used during mass spectrometry.
3.1 ASCORBIC ACID DECOMPOSITION CASCADE
Once ascorbic acid is decomposed into DHA, it can then rapidly convert into a
variety of transformation products possessing absorption maximum between 240 and 350
nm. Eiji kimoto et al (2). Studied the decomposition cascade of ascorbic acid. Using
electrochemical detection-HPLC analysis. Figure 3.2 shows the structures of compounds
involved in this cascade. They suggested a possible decomposition pathway of DHA. DHA
is easily delactonized into 2,3-diketo-L-gulonic acid(DKG). DKG undergoes isomerization
to form the 6-membered R-345. DKG solution may also be subjected to decarboxylation
to form L-xylosone (XLS) as reported by whiting and coggins. (1) Subsequently
transformation produces various five-carbon.

XLS is converted to Compound VI. Compound VI is dehydrated to from compound
VIII, the unsaturated α- keto acid, which is further dehydrated to produce 2 Furoic acid
(2FA) (compound XI) and/or 3OH2P (Compound XII) of the 2-pyrone form. As an
alternative pathway XLS is converted to enediol form, Compound VII. Its aldehyde group
is oxidized to carboxyl group which is lactonized to form EAsA. Intramolecular redox
reaction of compound VII leads to rearrangement from the aldehydic to the carboxylic
group and from the hydroxymethyl at the
C (5) position to the methyl group, thus producing compound X. It undergoes ring
closure to form MDT. Otherwise, the aldehydic group of compounds VII reamins intact.
It dehydrated and reduced i.e. loss of oxygen to form compound IX of the structure.
Compound IX is dehydrated to form FF of the furan form, or it is rearranged to form the
bialdehydic structure as an unstable intermediate which undergoes ring closure easily to
form RA.
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Identification of the actual compound that initiated NO release form RSNOs is
extremely important. If the identified compound is stable and non-toxic it could provide a
means that initiate RSNO decomposition in polymeric materials or endogenously from
RSNOs present in biological systems. For example, a polymer such as medical grade
polyurethane doped with the reducing agent could be formulated such that when exposed
to blood the active agent slowly leaches from the material, decomposing circulating
nitrosothiols and preventing thrombus formation on the device.

Figure 3.2 Represents structure of the 5-Carbon compounds involved in the cascade.

50

51

52

Figure 3.3 Possible reaction pathway for the transformation products of ascorbic
acid [2].

3.2 EXPERIMENTAL PROCEDURE FOR MASS SPECTROSCOPY
Reagents and chemicals of highest grade was obtained from Sigma-Aldrich (St.
Louis, MO, USA). Nitrogen gas was purchased from General Air Service and Supply
(Denver, CO, USA). DHA and 2FA were also purchased from Sigma-Aldrich. Methanol
along with di-ionized water were used as solvent for mass spectroscopy in 50-50 % ratio.
Thermo Finnigan LCQ Advantage Ion-Trap was used for mass spectroscopy.
The Finnigan LCQ Advantage is an ion trap mass spectrometer. This instrument is
capable of performing both single stage LC/MS a double stage LC/MS/MS. Sample
solution is introduced to the mass spectrometer via loop injection. It uses electrospray
ionization (ESI) ESI results in the generation of highly charged droplets directly from the
infused solution. Multiply and/or singly charged analyte molecules desorb from the
sprayed droplets and are sampled through the mass spectrometer for mass analysis. Rest of
the equipment consists of quadruple ion trap where the ions are trapped followed by a
photodiode array (PDA) detector. Compounds collected from HPLC separation were used
an input samples for mass spectroscopy. 500µl of samples is injected, data is recorded for
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11 minutes. After running each sample solution of methanol and de-ionized water is used
for cleaning injector module. Once it is cleaned another sample with same amount is
injected for analysis.

3.3 DATA ANALYSIS FOR MASS SPECTROSCOPY
Upon introducing the eluent from the HPLC peak of interest into the MS, the
components were first ionized. The ions then travel to the mass analyzer and arrive at the
different part of the detector according to the mass/charge ratio. After the ions make contact
with the detector useable signals are generated and displayed on the computer. Yaxis is
labelled as the relative abundance, which is actually the relative intensity. This is the
intensity relative to the tallest peak in the spectrum with the tallest peak set to 100%. Xaxis is the mass divided by the charge ratio m/z. since the charge is always +1 with ESI,
the m/z ratio always represent mass. All the data collected is in the positive ion mode since
there were compounds detected in the negative ion mode.
First MS analysis was carried out on the HPLC separated compounds for
decomposed ascorbic acid. Figure 3.3 represents MS data for HPLC separated decomposed
ascorbic acid. Spectra show a number of peaks which suggests presence of multiple
compounds. Each peak obtained from the HPLC separation was further broken down for
full mass analysis. Compounds with m/z charge ratio higher than 550 m/z did not break
down into smaller fragments. However, peak with 430.8 m/z ratio was further broken down
to 158.9 m/z ratio. Using the ascorbic acid decomposition cascade as reference we
suspected this peak to be either dimers of dehydroascorbic acid or 2-furoic acid keeping
their molecular mass in account with either addition or donation of hydrogen ions. After
narrowing it down to two compounds i.e. dehydro-ascorbic acid and 2-furoic acid we
performed MS on these two compounds to see if we could find any overlap.
Reference material 2-Furoic acid and Dehydro-ascorbic acid of highest purity was
purchased from Sigma-Aldrich (St. Louis, MO, USA) for testing NO release and perform
mass spectroscopy to see if any compounds overlap with the existing data. Five different
samples were prepared for both MS analysis and then as pure substances that would
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directly initiate release of NO from SNAP measured in the chemiluminescence detector.
Table 3.1 lists compounds selected for further testing suggested from MS analysis: Table 3.1 Represents the compounds selected for testing along with their respective
concentration.
Compound I

2-furoic acid (2FA)

1mm

Compound II

Dehydro-ascorbic acid 1mm
(DHA)

Compound III

DHA + 2-furoic acid

1mm(DHA) 50% +
1mm 2-FA (50%

Compound IV

2-furoic
acid
Ascorbic acid

Compound V

Ascorbic acid

+ 1mm (2FA) 50% +
1mm Ascorbic acid
50%
1mm

Table 3.2 Represents m/z ratio of each of the compound tested, it also includes a further
breakdown of the m/z ratio which were possible.
Compound
HPLC
decomposed
acid

m/z ratio

m/z
ratio
breakdown)

separated 430.8
ascorbic

(Further

158.9

2-Furoic acid

424.9

157

DHA + 2FA

424.9

157

Ascorbic acid

178

Ascorbic acid + 2FA

Multiple peaks

Mass spec analysis was performed on the HPLC separated compounds, to further
identify the exact compound mass spec analysis was performed on all of the five
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compounds listed in Table 3.1 to find any overlap with the HPLC separated compounds.
2-Furoic acid had compound with m/z ratio of 424.9 which was found in decomposed
ascorbic acid, i.e. compound with compound with 424.9 m/z broke down into 157m/z as
seen in figure 3.5(Figure 3.5 shows mass spec data for 2-FA). So, did the combination of
DHA + 2-FA losing a pair of hydrogen atoms, i.e. compound with m/z 424.9 which further
broke down in to 157 m/z like that found in Figure 3.1(Figure 3.4 shows Mass spec data
for DHA + 2FA). Since there is an overlap of m/z ratio from both 2FA and 2FA + DHA
with the originally separated decomposed ascorbic acid it was concluded that either 2FA
or DHA is one of the decomposition products of the ascorbic acid responsible for the large
amount of NO release. Further analysis on the compound i.e. 2FA + Ascorbic acid shows
no overlap in m/z ratio with the HPLC separated decomposed ascorbic, which concludes
that ascorbic acid suppresses the presence of 2-furoic acid and forms a complex mixture,
that might be one of the reasons why ascorbic acid produces a lower amount of NO as
compared to 2 furoic acid. (Figure 3.9 & 3.10 describes it in more detail)

Figure 3.5 represents MS data for 1mm 2-furoic acid. It also showed presence of
multiple peaks. Peaks with m/z charge ratio above 550 did not show any break down
fragments in full mass analysis of the spectrum, however the peak with m/z ratio 424.9 was
further broken down into peak with m/z ratio 157. Which indicates similar compound as
seen in HPLC separated decomposed ascorbic acid.
Similarly Figure 3.6 represents MS data for the combination of DHA and 2-FA
(1mm). Data reported presence of the same compound with m/z ratio of 424.9 which could
be further broken down into fragment of m/z ratio 157.
Figure 3.7 represents MS data for fresh ascorbic acid sample (1mM). Molecular
mass of ascorbic acid is 176 g/mol so the m/z ratio should be 177 with the addition of one
hydrogen atom, which is seen in the figure 3.5 ascorbic acid with peak of m/z ratio 177.
Figure 3.8 represents MS data for the combination of fresh ascorbic acid with
2furoic acid. Data showed no overlap with any of the peaks seen earlier, which lead us to
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believe that ascorbic acid suppress the presence of 2-furoic acid to form some other
compounds.

Figure 3.4 Mass Spectroscopy data after HPLC Separation for Decomposed Ascorbic acid.
Left side represents spectrum view over the range of 200 – 1000 m/z ratio. Right side
represents Further breakdown of 430.8 m/z ratio.
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Figure 3.5 Mass Spectroscopy data for 2-Furoic acid. Left side represents spectrum view
over the range of 200 – 2000 m/z ratio. Right side represents Further breakdown of 424.9
m/z ratio.

Figure 3.6 Mass Spectroscopy data for DHA + 2FA. Breakdown of 424.9 m/z ratio.
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Figure 3.7 Mass Spectroscopy data for Fresh ascorbic acid sample.

Figure 3.8 Mass Spectroscopy data for Fresh ascorbic acid + 2-furoic acid in 50-50% ratio.
NO overlap of compounds for comparing with decomposed ascorbic or 2-furoic acid mass
spec data.
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3.4 DETERMINATION OF NO GENERATION
To calculate the amount of NO release from each compound we designed the
folloing expeperiemnt. Nitrogen was used as a sweeping gas for all the four analyses.
SNAP crystals of 0.8 mg were used in each experiment. SNAP was placed in a dark vial
and connected to the NO analyzer with the sweeping gas. After 10 minutes, 2ml of
Phosphate Buffer Saline (PBS) of concentration mixed with Chelex 100 is added to the
SNAP crystals. This causes NO release because of reaction between trace metal
contaminants and SNAP. After a period of 1 hour we injected the one of the four
compounds listed above recording the NO profile, as the readings reaches a plateau we
inject 1mm CuCl2 to it in order to initiate complete decomposition of the SNAP remaining
in solution.

3.5 DATA ANALYSIS FOR NO ANALYZER
Each set of experiments was performed in triplicates. Dark colored vial was used
to avoid NO release through photoinitiation. Chelex 100 is used a chelating agent for
purification of compounds via ion exchange. Copper chloride was added in the end just to
show that system still contains nitric oxide.
Initial readings show zero nitric oxide released for first 10 mins which indicates
that SNAP crystals used are stable. Upon addition of PBS it releases nitric oxide. Once the
PBS readings reaches a plateau we inject the compound of interest. Data shows that 2Furoic acid releases maximum amount of NO i.e. 900 PPB. When ascorbic acid is
combined with 2-furoic acid the amount of NO released is almost 1/3 in comparison to that
intuited from pure 2-furoic acid.
Table 3.3 Represents Amount of NO released from 2-furoic acid, dehydroascorbic acid and
fresh ascorbic acid
Compounds

Amount of NO Released

2 Furoic acid

101x10-08 moles

Dehydroascorbic acid

1.01x10-8 moles

Fresh Ascorbic acid

28.2x10-08moles
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Table 3.4 Represents Amount of NO released from 2-furoic acid + ascorbic,
dehydroascorbic acid + ascorbic acid and fresh ascorbic acid
Compounds

Amount of NO Released

2 Furoic acid + ascorbic acid

15.1x10-8 moles

Dehydroascorbic acid + ascorbic

11.4x10-8 moles

2 furoic acid

30.4x10-8 moles

Figure 3.9 shows a direct comparison between the NO released from the 2-Furoic
acid, Dehydroascorbic acid and Fresh ascorbic acid. Last spike in the Figure is due to
injection of Copper Chloride which reacts with SNAP to give huge amount of NO.
From this data, it is very suggestive that 2-furoic acid or dimers of this compound
are responsible for initiating NO release from RSNOs.

When 2furoic
acid is injected
When fresh
ascorbic acid is
injected

When
dehydroascorbic
acid is injected

Figure 3.9 Direct comparison between 2-furoic acid, Dehydroascorbic acid and fresh
ascorbic acid. 2-furoic acid releases highest amount of NO.
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Figure 3.10 Direct comparison between 2-furoic acid, dehydroascorbic acid & fresh
ascorbic acid. 2-furoic acid releases highest amount of NO.

3.6. CONCLUSION
The goal of the project was to identify the compound responsible for production of
NO. In order to do that there was a need to study and identify decomposition products of
ascorbic. Compound separation was done using HPLC. Once the compounds were
separated real time NO analysis was carried out on both decomposed ascorbic acid and
fresh ascorbic acid taken from HPLC using 3-D printed device as a medium. It was
concluded that decomposed ascorbic acid produces more NO compared to fresh ascorbic
acid. Next step was to identify the compounds present in the decomposed ascorbic acid and
then test those compounds separately for NO generation. Identification of compounds were
carried out using mass spectroscopy.
Based on the MS data and the testing of pure compounds from the ascorbic acid
decomposition cascade, the potential compounds responsible for the release of NO from
RSNOs was narrowed down to either DHA or 2-FA. All the compounds tested showed
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some amount of NO released, but 2-FA, by itself, showed almost three times the amount
of NO released compared to other compounds. Combination of both fresh ascorbic acid
and 2-FA release NO similar to that of the combination of DHA and 2-FA which indicates
that the ascorbic acid suppresses the presence of 2-furoic acid in the system, similar to be
said for DHA since it is an immediate decomposition product of ascorbic acid.
Thus, both the MS data where peak of m/z i.e. 424.9 ratio of the 2-furoic acid
coincides with the peak of the HPLC separated decomposed ascorbic acid. Furthermore,
the NO data showing maximum amount of NO released is from 2-FA out of the
combination of all the compounds. Therefore, it is likely that 2-furoic acid is the agent that
causes NO release instead of high concentrations of ascorbic acid.
2-furoic acid is a carboxylic acid, consisting of a five-membered aromatic ring. It
is an organic product most widely used in food products as a preservative and a flavoring
agent. 2-furoic acid is no-toxic. Whole goal of the project was to eventually develop a
polymer with 2-furoic acid in its backbone, which can be coated on a medical device upon
contact with blood it leaches and reacts with biological RSNOs to produce NO.
Since 2-furoic acid is potentially used in many of the food products so the human body is
not subjected to any toxic products.
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4. CONCLUSION AND FUTURE DIRECTIONS
With the increasing number of illness which cannot be tackled with medication
alone there is an increasing need for implantable medical devices. Studies for improving
the quality and design of implantable devices has been carried out since early 1960s and
tremendous progress has been made in miniaturization of reliable devices that are capable
of monitoring and improving physiological function in vitro. There is still a stark crop in
performance when these devices are actually placed in the complex and dynamic in vivo
environment. Understanding the host response is extremely important in development of
implantable devices. One of the emerging solution is nitric oxide (NO) releasing polymer
coatings on

implanted medical devices. The focus of the work described herein is to

identify the NO generating decomposition product of ascorbic acid.
Nitric oxide is potentially viable option to help control the coagulation cascade and
wound healing responses, i.e. driving pathways that determine ultimate host response. NO
has a diverse array of functions in vivo including help controlling the blood vessel tone and
adhesion receptor expression. NO is also a potent inhibitor of platelet aggregation and
activation. NO is also involved in endothelium cell and smooth muscle cell proliferation;
it has a direct role in destruction of bacteria during phagocytosis by macrophages. Vascular
endothelium cells are estimated to generate NO flux of 1.0-4.0 x 10

-10

mol·cm-2 min-1

continuously and is the primary basis for the non-thrombogenic properties of the vascular
endothelium, surface which elicits normal host response (i.e., the coagulation cascade is
not activated) despite constant contact with precursor molecules to the intrinsic coagulation
cascade. The endogenous NO supply diffuses into the lumen of the blood vessels and
smooth muscles cells that surrounds all the arteries where it plays an important role in
preventing platelet activation in healthy blood vessels.
The innate physiological functions of NO make it a strong candidate for improving
the biocompatibility of the implanted devices. NO releasing sensors will be capable of
controlling both platelet adhesion and activation along with minimizing vasocontraction.
NO releasing subcutaneous implanted sensors have been shown to increase blood flow to
the sensor surface, increase transfer of analyte, reduce bacterial adhesion and reduce
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fibrous encapuslation. Because the half-life of NO in the biological system is 0.5-1.8ms,
the NO generated should not create any systemic effects.
There are three known mechanics of NO generation from S-nitrosothiols
(RSNOs). Copper mediated decomposition in which Cu2+ is first reduced to Cu+ and then
Cu+ reduces RSNOs to NO. Common species used to reduce Cu2+ to Cu+ are free thiolate
ions present as impurities in RSNO solutions and ascorbic acid. Ascorbic acid itself has
been reported to directly interact with RSNOs when it is present at greater than millimolar
concentrations to directly reduce RSNO to NO and produce free thiol groups. The
mechanism of this reaction is not known. The third known mechanism of NO generation
from RSNOs is by means of photoinitiation.
The work presented here focused on elucidating the species responsible forNO
generation from ascorbic acid. Literature states that ascorbic acid when reacts with RSNOs
it releases NO if present in more than millimolar concentration but we have shown that it
is not actually ascorbic acid that causes NO release, rather a product that results from
ascorbic acid decomposition under ambient conidtions . When ascorbic acid decomposes,
it produces a complex mixture, it is one of these compounds that is actually responsible for
the NO generation. Main goal of this project was to study the decomposition products of
ascorbic acid and identify the compound responsible for generating NO.
UV-VIS spectroscopy was used to identify the absorption wavelength for both fresh
ascorbic acid and decomposed ascorbic acid. Data suggests that peak absorption
wavelength of ascorbic acid is 263nm which is consistent with the literature.
Decomposed ascorbic acid showed several peaks with consistent change of absorbance.
Additionally, the absorbance of the ascorbic acid peak at 263nm is reduced in intensity
from 0.56 to 0.25 after 8 days of passive decomposition, indicating a significant loss of
parent compound. This confirms that decomposition products of ascorbic acid are present
in substantial quantities in the solution. The peaks resulting from these compounds have
absorbance maximum ranging from 200 – 400 nm. This information was vital because it
will help setup up the detection range for HPLC while physically separating these
compounds.
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HPLC system was used for separation of these decomposition compounds. Under
the isocratic separation conditions utilized, ascorbic acid has a retention time 1.407 minutes
and no other compound being eluted from fresh ascorbic acid sample. Decomposed
ascorbic acid showed two peaks at 0.691 minutes and 1.198 minutes which surely suggests
presence of more than one compound in decomposed ascorbic acid sample. A UVSpectrum analysis was carried out on the two peaks obtained which showed how the
absorbance for the peaks changes over time. Th UV-Vis spectrum obtained from the diode
array detector in the HPLC system showed that for the first peak absorbance is 0.05 and
gradually changes as the peak descend and when the second peak ascends, the absorbance
is 0.16 indicating a different compound and it reaches to 0.2 when the peak descends; Once
again providing a clear evidence of presence of more than one compound.
To identify which component(s) in these 2 solutions (fresh and decomposed
ascorbic acid) was responsible for initiating NO release from SNAP, a novel device was
designed and used to couple the separation capacity of the HPLC with the direct NO
measurement using NO analyzer. NO analysis was performed on Fresh ascorbic acid,
decomposed ascorbic acid and a blank sample. The amount of NO released from the
decomposed ascorbic acid is more than twice the amount released from fresh ascorbic acid.
This proves that when ascorbic acid decomposes it release more NO than fresh ascorbic
acid, which concludes that a new compound is formed when ascorbic acid decomposes.
Table 4.1 Represents Total NO released by blank sample, fresh and decomposed ascorbic
acid
Compounds

Total NO released ±(SD)

Fresh ascorbic acid

170x10-12 (1.07x10-10) moles

Decomposed ascorbic acid

350x10-12 (3.50x10-10) moles

Blank sample

6.29x10-12 (6.29x10-12) moles

Next step was to identify the compound responsible for NO release. Mass
Spectroscopy was used for identifying decomposition product of ascorbic acid. Mass
spectrum of a sample is a pattern representing the distribution of ions by mass (more
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correctly: mass-to-charge ratio) in a sample. First MS analysis was carried out on the HPLC
separated compounds for decomposed ascorbic acid. Spectrum showed number of peaks
which suggests presence of multiple compounds. Each peak was further broken down for
full mass analysis.
Compounds with m/z charge ratio higher than 550 m/z (mass by charge ratio) did
not break down into smaller fragments. However, peak with 430.8 m/z ratio was further
broken down to 158.9 m/z ratio. Using the ascorbic acid decomposition cascade as
reference we suspected this peak to be either dimers of dehydroascorbic acid or 2-furoic
acid keeping their molecular mass in account with either addition or donation of hydrogen
ions. After narrowing it down to two compounds i.e. dehydro-ascorbic acid and 2-furoic
acid we performed MS on these two compounds to see if there was an overlap.
Reference material 2-Furoic acid and Dehydro-ascorbic acid of highest purity was
purchased for testing NO release and perform mass spectroscopy to see if any compounds
overlap with the existing data.
Table 4.2 lists compounds selected for further testing suggested from MS analysis:
Compound I

2-furoic acid (2FA)

1mm

Compound II

Dehydro-ascorbic acid 1mm
(DHA)

Compound III

DHA + 2-furoic acid

1mm(DHA) 50% +
1mm 2-FA (50%

Compound IV

Compound V

2-furoic
acid
Ascorbic acid

Ascorbic acid
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+ 1mm (2FA) 50% +
1mm Ascorbic acid
50%
1mm

Table 4.3 represents the compounds selected for testing along with their respective
concentration.
Compound
HPLC
decomposed
acid

m/z ratio

m/z
ratio
breakdown)

separated 430.8
ascorbic

(Further

158.9

2-Furoic acid

424.9

157

DHA + 2FA

424.9

157

Ascorbic acid

178

Ascorbic acid + 2FA

Multiple peaks

Table 3.2 Represents m/z ratio of each of the compound tested, it also includes a
further breakdown of the m/z ratio which were possible.
2-Furoic acid had compound with m/z ratio i.e.424.9 which was found in
decomposed ascorbic acid i.e. compound with 424.9 m/z broke down into 157m/z. So, did
the combination of DHA + 2-FA losing a combination of hydrogen atoms i.e. compound
with m/z 424.9 which further broke down in to 157 m/z. Since there is an overlap of m/z
ratio from both 2FA and 2FA + DHA with the originally separated decomposed ascorbic
acid it was concluded that either 2FA or DHA is one of the decomposition product of the
ascorbic acid responsible for the large amount of NO release. Further analysis on the
compound i.e. 2FA + Ascorbic acid shows no overlap in m/z ratio with the HPLC separated
decomposed ascorbic, which concludes that ascorbic acid suppresses the presence of 2furoic acid and forms a complex mixture, that might be one of the reasons why ascorbic acid
produces less amount of NO as compared to 2 furoic acid.

Last step was to perform NO analysis on these compounds to provide definitive
evidence that 2-furoic acid is the actual compound that causes NO release. Data showed
that 2-Furoic acid releases maximum amount of NO i.e. 1.01x10-6 moles. When ascorbic
acid is combined with 2-furoic acid the amount of NO released is almost 1/3 in comparison
to that intuited from pure 2-furoic acid. From this data, it is very suggestive that 2-furoic
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acid or dimers of this compound are responsible for initiating NO release from RSNOs.
Therefore, it is likely that 2-furoic acid is the agent that causes NO release instead of high
concentrations of ascorbic acid.
For the scope of the experiments a very basic design of a 3-D printed device was
created, which functioned sufficiently under these initial conditions. For future work, the
3-D printed device should be optimized i.e. the size and shape of the reaction chamber,the
angles for the incoming solutions into the reaction chamber, the dimensions of the channels
into the reaction chamber. These optimizations should make the device generally more
applicable to other potential HPLC separations coupled to gas reactant products.
2-furoic acid is a carboxylic acid, consisting of a five-membered aromatic ring. It
is an organic product most widely used in food products as a preservative and a flavoring
agent. 2-furoic acid is no-toxic. Whole goal of the project was to eventually develop a
polymer with 2-furoic acid in its backbone, which can be coated on a medical device upon
contact with blood it leaches and reacts with biological RSNOs to produce NO. Since 2furoic acid is potentially used in many of the food products so the human body is not
subjected to any toxic products. Because this a simple compound that is stable, there are a
wide variety of different conditions in which it may be used to create NO generating
materials and surfaces.
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